NTHI

Neonc Technologies, Inc.distress 9/10 · high distress / dilution risk

$3.49-5%today-71% from 52w high

neonc.com5 employeesFounded 2005Calabasas, CABiotechnology

Oncology 1

Lead: glioblastoma

Revenue

pre-revenue

Liquidity

$0M

Runway

0.0 yrs

Shares 1y

+36%

Price & events

-60.1% over 6M

CatalystRating changeDilutionFinancingdashed = today

-4.9%

+7.4%

-28.5%

-27.1%

-61.0%

-29.5%

—

-71.2%

All

Overview

Market Cap: $90.79M
Volume: 1.30K
52 Week Range: $3.25 – $12.09
Total Shares: 26.01M
Float Shares: 8.83M
Short %: 3.61%
% Held by Insiders: 58.49%
% Held by Institutions: 11.77%
RVOL: 0.01x

Pipeline stages · 3 programs

NEO100

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2026-10

NEO212 Oral Capsule, Ipilimumab, Pembrolizumab

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2027-02-28

Perillyl alcohol

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

Pipeline · 4 trials · 3 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
2026-10 Estimated 50% readout ~2026-10-31	Phase 1	NEO100fast trackorphanrare pediatric	Pediatric Tumor of CNS, Pediatric Tumor of Brain, Diffuse Midline Glioma, H3 K27M-Mutant, Pediatric Tumor of Brain Stem, Pineocytoma, Choroid Plexus Carcinoma, Childhood, Spinal Cord Tumor, High Grade Glioma	—	not yet recruiting
2026-12-30 Estimated 50% readout ~2027-02-13	Phase 2	NEO100fast trackorphanrare pediatric	Residual, Progressive or Recurrent Grade II or III Meningioma	—	recruiting
2027-02-28 Estimated 50% readout ~2027-04-14	Phase 1/2	NEO212 Oral Capsule, Ipilimumab, Pembrolizumabfast track	Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability-High Solid Malignant Tumor, Mismatch Repair Deficient Solid Malignant Tumor, Microsatellite Instability-High Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Squamous Cell Carcinoma, Urothelial Carcinoma	—	recruiting
2026-03-30	Phase 1/2	Perillyl alcohol	Glioblastoma Multiforme	49	recruiting

Upcoming readouts & decisions · our signals

1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.

Catalyst news & presentations · 11

2026-08-14Estimated 45%earningsEarningsEarnings releaseyahoo
by the end of July 2026Estimated 45%readoutPhase 2NEO100 · Top-line data from fully enrolled Phase 2a trialSEC 8-K
2026-07-15fda agreementNEO212 · FDA provided written feedback on CMC development plan, including requirements for capsule-to-tablet transition and parallel late-stage clinical development.SEC 8-K
6 to 8 months after enrollment completionreadoutPhase 2NEO100 · Topline readout of Phase 2 NEO100-01 trialSEC 8-K
2026-06-23fda agreementNEO100 · UAE DOH granted IND status for NEO100 across multiple protocolsSEC 8-K
2026-06-16fda agreementNEO212 · DOH Abu Dhabi granted IND status for NEO212.SEC 8-K
March 4, 2026conferencedata presentationsecondaryPhase 1NEO212 · present initial data from Phase 1 dose-escalation portion of NEO212-01 Phase 1/2 clinical trialSEC 8-K
this yearenrollment completesecondaryPhase 2NEO100 · Complete enrollment for Phase 2 NEO100-01 trial in GBMSEC 8-K
Wednesday, November 12, 2025 at 9:00 a.m. Eastern TimereadoutPhase 1/2NEO100 · Present data updates from ongoing Phase 1/2a NEO100-1 clinical trial and compassionate use program, including MRI response, PFS, and OS trends.SEC 8-K
2025-07-08partnershipNEO100, NEO212 · Signed non-binding term sheet with Quazar Investment for $50M equity investment to form NuroMENA and NuroCure for MENA clinical trialsSEC 8-K
2025-03-27partnershipNEO100 · Strategic partnership with CBCC Global Research to conduct NEO100-01 trial at 30 sites in IndiaSEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 26,013,136 · 6 offerings/1y · 8 PIPEs

2026-06-23EFFECTshelf_effective
2026-06-23424B5offering
2026-06-15S-3shelf_registration
2026-06-128-Kprivate_placement
2026-04-248-Kprivate_placement
2026-04-16EFFECTshelf_effective
2026-04-16424B5offering

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

strong buy · target $16 (+358% upside) · 3 analysts

2026-05-26BTIGBuy
2026-05-19Alliance Global PartnersBuy
2026-05-18Maxim GroupBuy
2026-04-24BTIGBuy

Competitors — glioblastoma

BNTXBioNTech SE$23.1B · D1
IBRXImmunityBio, Inc.$7.8B · D5
TNGXTango Therapeutics, Inc.$4.0B · D5
BDTXBlack Diamond Therapeutics, Inc.$104M · D5
SHPHShuttle Pharmaceuticals Holdings, Inc.$17M · D10
MBIOMUSTANG BIO, INC.$15M · D5
INABIN8BIO, INC.$12M · D7
CNSPCNS Pharmaceuticals, Inc.$8M · D10
CURXCuranex Pharmaceuticals Inc$6M · D8

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.